CRC

Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Tuesday, January 9, 2024

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

Retrieved on: 
Friday, January 12, 2024

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that it has petitioned the United States Patent and Trademark Office (USPTO) for inter partes review challenging the patentability of United States Patent No.

Key Points: 
  • Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that it has petitioned the United States Patent and Trademark Office (USPTO) for inter partes review challenging the patentability of United States Patent No.
  • 11,634,781 (“the ’781 patent”) owned by Exact Sciences.
  • The fecal tests for detecting blood protein and nucleic acids recited by the claims were known and routine.
  • The claimed method of the ’781 patent is obvious, and the claims directed to the method are invalid.

Cognitive Research Corporation Appoints Dr. Tom Zoda as Chief Executive Officer

Retrieved on: 
Tuesday, January 9, 2024

ST. PETERSBURG, Fla., Jan. 9, 2024 /PRNewswire/ -- Cognitive Research Corporation ("CRC"), a leading Central Nervous System (CNS)-focused clinical research and drug development organization (CRO), is pleased to announce that clinical research industry veteran, Dr. Tom Zoda has been appointed as Chief Executive Officer and a member of the Board of Directors effective immediately.

Key Points: 
  • ST. PETERSBURG, Fla., Jan. 9, 2024 /PRNewswire/ -- Cognitive Research Corporation ("CRC"), a leading Central Nervous System (CNS)-focused clinical research and drug development organization (CRO), is pleased to announce that clinical research industry veteran, Dr. Tom Zoda has been appointed as Chief Executive Officer and a member of the Board of Directors effective immediately.
  • Dr. Zoda brings nearly 30 years of clinical research industry experience to CRC.
  • Most of his career has been dedicated to the CNS clinical research space through a variety of roles in operations, business development, and executive leadership.
  • Most recently, Dr. Zoda served as COO for Apex Innovative Sciences and CenExel Clinical Research, both CNS-focused clinical research site networks.

VESA Announces DisplayPort Updates and Extensions for Gaming and Automotive Market at CES

Retrieved on: 
Monday, January 8, 2024

BEAVERTON, Ore., Jan. 8, 2024 /PRNewswire/ -- The Video Electronics Standards Association (VESA®) today announced that it has published the latest update to DisplayPort, version 2.1a. This update replaces the VESA certified DP40 ultra-high-bit-rate (UHBR) cable specification with a new VESA certified DP54 UHBR cable spec to enable up to four-lane UHBR13.5 link rate support (a maximum throughput of 54 Gbps) over a two-meter passive cable. As a result, the DisplayPort 2.1a update effectively doubles the passive cable length for UHBR13.5 GPU-to-display connections—which previously could only be supported through a DP80 UHBR cable—providing consumers with greater flexibility in their gaming or workstation setup.

Key Points: 
  • VESA also announces it has published a new Automotive Extension Services protocol specification for both DisplayPort 2.1a and the latest version of VESA's Embedded DisplayPort (eDP) specification, version 1.5a.
  • Silicon manufacturers are already adopting VESA's Automotive Extension Services protocol today for chipsets that will be integrated in future vehicles.
  • Most automotive displays currently use DisplayPort or eDP to carry video data from the central vehicle computer to the displays.
  • The VESA Automotive Extension Working Group, which is driving the new Automotive Extension specification protocol, is open to all VESA members.

Accanto Health appoints seasoned behavioral healthcare leader as CEO

Retrieved on: 
Monday, January 8, 2024

ST. PAUL, Minn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accanto Health, a national leader in eating disorder specialty care and behavioral health services, announced the appointment of veteran behavioral health executive Dr. Tom Britton as CEO this week.

Key Points: 
  • ST. PAUL, Minn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accanto Health, a national leader in eating disorder specialty care and behavioral health services, announced the appointment of veteran behavioral health executive Dr. Tom Britton as CEO this week.
  • Accanto Health encompasses renowned brands: The Emily Program, Veritas Collaborative, and Gather Behavioral Health.
  • Britton expressed his excitement about joining Accanto Health, stating, “It is an incredible honor and privilege to join Accanto Health in the role of CEO.
  • On a personal level, he feels passionate about behavioral health in part due to his own experience with addiction and recovery.

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Retrieved on: 
Monday, January 8, 2024

WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today highlighted recent advances across its clinical pipeline and reported encouraging preliminary safety data from the first three dose levels in the ongoing Phase 1 trial evaluating XTX301, a tumor-activated IL-12, in patients with advanced solid tumors.

Key Points: 
  • “For more than 20 years, IL-12 development has been relentlessly pursued due to its unique potential to treat immunologically cold tumors.
  • However, treatment with IL-12 has remained out of reach due to the lethal toxicities associated with systemic administration,” said René Russo, Pharm.D., president and chief executive officer of Xilio.
  • Xilio today announced encouraging preliminary safety data from its ongoing Phase 1 trial evaluating XTX301 as a monotherapy in dose escalation in patients with advanced solid tumors.
  • XTX301 was generally well-tolerated across all dose levels with no dose-limiting toxicities observed in patients as of the data cutoff date.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Retrieved on: 
Thursday, January 4, 2024

Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

Key Points: 
  • Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
  • The collaboration with Inspirna builds on Merck KGaA, Darmstadt, Germany’s long-standing commitment to the colorectal cancer community.
  • “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.

Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna

Retrieved on: 
Thursday, January 4, 2024

Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds.

Key Points: 
  • Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds.
  • Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
  • The collaboration with Inspirna builds on Merck’s long-standing commitment to the colorectal cancer community.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).